Anticancer agents

To improve treatment outcomes, multiple drugs of distinctive mechanisms but complementary anticancer activities are often used to enhance antitumor efficacy and minimize the risk of acquiring drug resistance. Specifically, the Law Lab investigates the synergistic effects of drug combinations to develop new therapeutic strategies, such as drug-induced targeting approaches, for cancer treatments. In addition, the lab is actively involved in studying other anticancer agents, including a mitochondrial disrupting peptide to induce the apoptosis of cancer cells, CXCR4-targeting delivery, anti-RAGE and Herceptin antibodies for immunotherapy, and docosahexaenoic acid as a sensitizer.